Abstract 159P
Background
The stromal component constitutes as much as 90% of pancreatic cancer specimens, dynamically interacting with the tumor and adapting into a pro-survival environment. This poses a clinical challenge, as biopsies often miss cancer by only sampling stroma. By leveraging AI and image analysis, we aim to extract informative cues from stromal interactions for novel cancer biomarker identification. This approach offers the potential for enhanced diagnostic precision and a deeper understanding of pancreatic cancer biology.
Methods
Anonymized digital scans of pancreatic cancer and chronic pancreatitis were sourced from the Centre Hospitalier de l’Université de Montréal. QuPath 0.4.3 aided slide annotation, with subsequent TIF annotation export. Staining normalization was performed via the Mitkovetta technique in Python. Our process involved deep-learning stromal segmentation, prioritizing >95% stromal tiles using Ilastik. Feature extraction was executed utilizing computer vision techniques (Haralick features), alongside the pre-trained and class-trained ImageNet deep-neural network, VGG16.
Results
Our annotated, normalized, automated, and 95% stroma-probability method generated for the training cohort 9829 cancer and 1638 mass-forming pancreatitis tiles, and 10776 cancer and 1211 pancreatitis tiles for the testing set. The table highlights the performance of the classical computer vision approach (Haralicks features extraction in RGB). Furthermore, transferring the ImageNet VGG-16 pre-trained model to our dataset managed to predict the presence of adjacent cancer at 86.6% accuracy. Table: 159P
| Training | Validation | |||
| Haralicks features | Cancer (N=9829) vs None (N=1638) | P | Cancer (N=10776) vs None (N=1211) | P |
| RGB-F2 | +66% | 7.52 X 10-308 | +8.2% | 1.37 X 10-9 |
| RGB-F15 | +54% | 3.28 X 10-272 | +8.5% | 8.57 X 10-11 |
| RGB F37 | +9.6% | 2.35 X 10-294 | +2.7% | 5.02 X 10-36 |
Conclusions
We demonstrate that normalized stromal tiles could predict the presence of cancer accurately just by their morphological features at HE staining. This highlights the importance of stroma for diagnostic purposes and can serve as the basis for future studies through multiplex imaging and spatial transcriptomics.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vincent Quoc-Huy Trinh.
Funding
Fonds de Recherche Québec Santé.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract